Kornimate/medical-research-clean huggingface dataset:
parkinson's disease in african american and caucasian patients

Conditions: Parkinson Disease

Summary: more than 10 million people worldwide are living with parkinson's disease (pd). while the actual number of african american (or black) patients with pd is unknown, it is clear that there are racial disparities in the access to health care, diagnosis, treatment and survival of pd. the lack of clear knowledge on the possibly lower pd prevalence among african americans compared to caucasians further calls for more research in this field. the university of chicago medicine is an ideal facility to study this topic, due to its location on the south side of chicago with a large african american (or black) population. by analyzing the demographics, socioeconomics and clinical features of pd patients in our center for research informatics in african american (or black) patients compared to the caucasians of similar geographical area, the investigators aim to work toward a better understanding of the unique features of pd in american american (or black) population, which might help improve the healthcare among this population in the chicago and possibly nationwide as well.

the first portion of the study will be a large medical electronic data based search and analysis of patients with pd on demographics, socioeconomic status and clinical features of pd patients. specifically, we will retrospectively identify pd patients on both races from the electronic medical database spanned from 1/1/2006 to 10/31/2017 and compared demographics, socioeconomic status (educations, incomes and insurances), co-morbidities (all categories, including mood, cognition and psychosis), treatment (medications for parkinsonism and major non-motor symptoms, and frequency and locations of healthcare) and survival, and identified factors associated with medication usage and survival. the second portion was designed to collect more detailed clinical assessments for information not available in the database and blood draws for genetic or candidate gene mutation analysis. unfortunately, this part of the study could not be carried out due to the covid-19 pandemic, which began shortly after completion of the first portion of the study. these assessments and analyses would have helped determine if there are significant differences in the clinical and genetic profiles between the african american (or black) and caucasian pd patients that account for their differences in clinical features and pd prevalence in these two populations.

Eligibility criteria:
inclusion criteria: * 15 years and older, confirmed diagnosis of pd, african american (or black) or caucasian race exclusion criteria: non-pd -
performance of clinical and biological diagnostic tests in reference to the recommended tests for the management of fungal peritonitis in intensive care

Conditions: Peritonitis

Summary: fungal peritonitis accounts for nearly 70% of invasive candidiasis in surgical resuscitation. their mortality is high, around 38% and their morbidity also with an increase in length of stay in intensive care, invasive ventilation times and an increase in the number of surgical revisions. currently, diagnostic and therapeutic management is based on clinical prognostic scores, of which the "peritonitis score" (ps) is still used as a reference. these scores are intended to best target a population eligible for probabilistic antifungal treatment pending the confirmation or not of the fungal characteristic of peritonitis by the fungal culture (gold standard). in case of severe peritonitis, if the ps is\> or = to 3, the clinician must start a broad-spectrum antifungal treatment which will be continued if the culture of the peritoneal fluid is positive to yeast. if it is \<3, it is not recommended to introduce an anti-fungal outside of very particular cases. in this situation, an anti-fungal treatment is only started if the direct examination of the peritoneal liquid made within 24 hours is positive to yeast or, failing this, to the reception of a positive culture several days later. however, recent reviews of the "peritonitis score" have emerged from the analysis of the "fungal peritonitis" subgroup of the amarcand ii study (underestimation in particular) , highlighting the difficulty of identifying this target population. in addition, none of these clinical scores have demonstrated superiority in guiding probabilistic antifungal therapy. direct examination of peritoneal fluid also suffers from low sensitivity. new diagnostic approaches using, among other things, blood markers (panfungal pcr, 1,3-beta-d-glucan, etc.) have developed in recent years. in particular, 1,3-beta-d-glucan has demonstrated superiority to the candida score in the early diagnosis of intra-abdominal candidiasis. \[8\]. his main interest lies in his strong negative predictive value. the association of these markers is another way of working to improve their diagnostic performance. the use of these blood markers is encouraged by european and international consensus, however, their dosage in the peritoneal fluid is still under study. one of the consequences of these diagnostic difficulties is the occurrence of inadequate prescriptions of antifungals in more than 40% of cases of fungal peritonitis in intensive care, or even more than 70% of cases in the case of any type of candidiasis. invasive. the investigators therefore seek to study the diagnostic performance of fungal markers (bdg and pcr) increasingly realized in chru de nancy in reference to the recommended tests (clinical (ps) and microbiological (ed and culture))


Eligibility criteria:
inclusion criteria: * any patient\> 18 years old who has been treated for peritonitis in intensive care unit in chru de nancy during year 2016 exclusion criteria: * none
evaluation of lofexidine for treatment of opiate withdrawal - 10

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to assess the safety of lofexidine in the treatment of opiate-dependent individuals.


Eligibility criteria:
inclusion criteria: m/f ages 21-50. meet dsm-iv criteria for opiate dependence. agree to conditions of the study and sign informed consent. exclusion criteria: psychiatric disorder that requires medication therapy. history of seizures. pregnant and/or nuring women. dependence on etoh or benzodiazepines or other sedative/hypnotics. acute hepatitis. other medical condtions that deem participation to be unsafe.

Keywords: opioid dependence
a 24-week study of fluticasone furoate/vilanterol inhalation powder in subjects of asian ancestry with copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the purpose of the study is to investigate the efficacy and safety of fluticasone furoate/vilanterol inhalation powder compared with placebo over a 24 weeks treatment period in subjects of asian ancestry with chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: * copd diagnosis define by ats(american thoracic society)/ ers (european respiratory society) * subjects of asian ancestry * valid informed consent * current or former smoker * \> or = 2 on the modified medical research council dyspnea scale at screening exclusion criteria: * pregnancy * a current diagnosis of asthma * alpha1-antitrypsin deficiency as the underlying cause for copd * other active, respiratory disorders * have lung volume reduction surgery within 12 months prior to screening * a chest x-ray or ct (computerised tomography) scan reveals evidence of clinical significant abnormalities not believed to be due to the presence of copd * poorly controlled copd: acute worsening of copd managed by corticosteroids, antibiotics, or treatments prescribed by a physician 6 weeks prior to screening, or requires hospitalisation due to poorly controlled copd 12 weeks prior to screening * lower respiratory tract infection requires antibiotics within 4 weeks prior to screening * other disease or abnormalities, in the opinion of the investigator, would put the safety of the subject at risk during the study or would affect safety or efficacy analysis if the disease/condition exacerbated during the study * subject with carcinoma that has not been in complete remission for at least 5 years, carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis. * subject has a history of hypersensitivity to any of the study medications or components of the inhalation powder. subject has a history of severe milk protein allergy that, in the opinion of the investigator, contraindicates the subject's participation will also be excluded. * subjects with a known or suspected history of alcohol or drug abuse within the last 2 years prior to screening * subjects who are medically unable to withhold albuterol, ipratropium for 4 hrs and/or theophylline for 12 hrs prior to spirometry testing. * subjects use a list of prohibited medications specified in the study protocol, including but not limited to traditional or herbal medications for the treatment of copd * subject requires long-term oxygen therapy or nocturnal oxygen therapy for greater than 12 hours a day * pulmonary rehabilitation: subjects who are in the maintenance phase are not excluded. * non-compliance * questionable validity of the informed consent * prior use of study medication or other investigational drugs * affiliation with investigator site
elevated plasma levels of timp-1 in patients with rotator cuff tear

Conditions: Rotator Cuff Tear

Summary: the aim of the study was to investigate the levels of matrixmetalloproteinases and their inhibitors in blood samples from patients with rotator cuff tears and compare with blood samples from healthy matched controls.

background: extracellular matrix remodeling is altered in rotator cuff tears, partly due to altered expression of matrix metalloproteinases (mmps) and their inhibitors. it is unclear if this altered expression can be traced as changes in plasma protein levels. we measured the plasma level of mmps and their tissue inhibitors (timps) in patients with rotator cuff tears. material and methods: blood samples were collected from 17 patients, median 61 (range 39-77) years, with sonographically verified rotator cuff tears (partial- or full-thickness). these were compared with 16 gender and age matched control persons with sonographically intact rotator cuffs. plasma levels of mmps and timps were measured simultaneously using luminex technology.

Eligibility criteria:
inclusion criteria: - degenerative rotator cuff tear verified by ultrasound exclusion criteria: * systemic joint disease such as rheumatoid arthritis * a fracture non-union * dupuytrens disease * frozen shoulder * tendinosis or rupture of any other tendons than in the rotator cuff * disorders of the spine such as disc disease,idiopathic scoliosis, spondylitis * cerebral or cardiovascular disease during the past year * abdominal or bowel disease * surgery or trauma during the past year * any infection during the last month * malignancy * treatment for the last month with medications that may affect mmps or timps (tetracycline, bisphosphonates, anti-inflammatory drugs, statins) * vigorous physical activity during the last 24 hours * inability to understand written and spoken swedish

Keywords: rotator cuff tear, matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, partial-thickness tear, full-thickness tear, plasma.
perioperative nutritional optimization in head and neck cancer patients

Conditions: Head and Neck Cancer

Summary: to determine whether nutritional optimization in head and neck cancer patients undergoing major surgery will decrease post-operative wound complications. the investigators hypothesize that nutritional supplementation with nestle impact advanced recovery (ar) will decrease the rate of wound complications after surgery

the purpose of this study is to determine whether nutritional optimization in head and neck cancer patients undergoing major surgery will decrease post-operative wound complications. it is likely that many head and neck cancer patients suffer from sarcopenia, and this contributes to many wound complications, including wound infection, dehiscence, fistula formation, and free flap tissue loss. the investigators hypothesize that nutritional supplementation with nestle impact advanced recovery (ar) will decrease the rate of wound complications after surgery

Eligibility criteria:
inclusion criteria: * age \>18 years. both men and women and members of all races and ethnic groups will be included. * patients must be diagnosed with cancer of the head and neck and must be surgical candidates. * patients must be indicated for major head and neck surgery, defined as surgeries with an anticipated post-surgical hospital stay of 4 or more days. examples of major surgeries include, but are not limited to, total laryngectomy, large oral cavity, oropharyngeal, salivary gland, or soft tissue resections requiring free flap or major regional flap (e.g. pectoralis major flap), and large skull base procedures requiring extensive skull base reconstruction. * patients must have cross-sectional body imaging (pet-ct or equivalent) performed within 4 weeks of study enrollment and available for review. * patient must be willing to receive nestle impact advance recovery for five days prior to planned surgery as well as for 5 days after surgery. * ability to understand and the willingness to sign a written informed consent document. * all adult men and women with cancer of the head and neck undergoing surgery by the study pi's at ui health will be considered for participation in this study without regard to race, gender or socioeconomic status. exclusion criteria: * patients with known distant metastases or other malignancies. * patients unable to tolerate oral intake by mouth or per enteral feeding tube. * patients with galactosemia. * patients who have received any investigational medication within 6 weeks of enrollment, or who are scheduled to receive an investigational drug during the course of the study. * patients currently taking impact or other immuno-nutrition products (arginine-containing supplements) will be excluded. other forms of nutritional supplementation, such as caloric supplementation, tube feeding, or other dietary supplements are allowed on study. * patients currently taking anabolic steroids will be excluded. patients taking corticosteroids are allowed on study. * psychiatric illness/social situations that would limit compliance with study requirements.
non alcoholic steatohepatitis in relation to visceral and subcutaneous fat

Conditions: NASH - Nonalcoholic Steatohepatitis

Summary: evaluate the relationship between the severity of fatty liver in nafld assessed by ultrasonography and ct and the visceral fat area measured by ct

non alcoholic fatty liver disease is one of the most common causes of chronic liver disease world wide . severe forms of nafld such as nonalcoholic steatohepatitis can progress to end-stage liver disease such as cirrhosis or hepatocellular carcinoma. therefore, investigating risk factors associated with hepatic steatosis is required to perform effective screening . hepatic steatosis develops for a variety reasons but obesity is the most common associated condition. obesity is considered a gateway disease and nafld is considered to be one of the phenotypes of metabolic syndrome, which is characterized by obesity with visceral fat accumulation, diabetes, hypertension and dyslipidemia. individuals with severe obesity have a disproportionately high risk of comorbidities including nonalcoholic fatty liver disease (nafld), cardiovascular disease and diabetes. the distribution of fat appears more important than the total fat mass in obesity .a predominantly upper body fat distribution increases the risks for the metabolic complications of obesity including hepatic steatosis especially when it is associated with increased intra abdominal fat . most "metabolically obese" normal weight subjects have some increase in adipose tissue mass and insulin resistance probably due to an increase in visceral fat. thus, subjects with a relatively low bmi can have gross increases in abdominal visceral fat, and others with a high bmi may have very little intra abdominal/visceral fat . several studies suggested visceral adiposity to be a clinical predictor of hepatic steatosis . in addition, the severity of fatty liver has been linked to the vat area as evaluated by ct.

Eligibility criteria:
inclusion criteria: * patient aged from 18years to 75years of both gender presented to alrajhi hospital with raised liver enzymes in period from october 2019 to june 2020 exclusion criteria: * patient with viral hepatitis history of drug intake auto immune hepatitis
safety and efficacy study of gevokizumab to treat active non-infectious uveitis

Conditions: Uveitis

Summary: the purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.


Eligibility criteria:
inclusion criteria: * diagnosis of non-infectious intermediate, posterior, or pan- uveitis in at least one eye * active uveitic disease in at least one eye * currently on one of the following stable treatment regimens for uveitis: oral corticosteroids; systemic immunosuppressive medication; a combination of oral corticosteroids with at least one systemic immunosuppressive medication * effective contraceptive measures exclusion criteria: * infectious uveitis and masquerade syndromes * isolated anterior uveitis * contraindication to mydriatics * history of allergic or anaphylactic reactions to monoclonal antibodies * active tuberculosis disease * history of recurrent infection or predisposition to infection; active ocular infection * pregnant or nursing women other protocol-defined inclusion/exclusion criteria may apply

Keywords: uveitis non-infectious uveitis intermediate uveitis posterior uveitis panuveitis
effect of intravaginal prasterone on symptoms of vva in women under treatment with an aromatase inhibitor for breast cancer

Conditions: Vaginal Atrophy in Breast Cancer Patients

Summary: the purpose of this study is to confirm the efficacy of intravaginal prasterone (dhea) on moderate to severe (ms) and most bothersome symptoms (mbs) of vulvovaginal atrophy (vva) due to natural, surgical or treatment-induced menopause, in women with breast cancer who are under treatment with an aromatase inhibitor.


Eligibility criteria:
inclusion criteria: main criteria: 1. natural, surgically- or treatment-induced postmenopausal women (non hysterectomized or hysterectomized) with breast cancer (stage 1 or 2) who is currently under treatment with an aromatase inhibitor and will remain on that treatment for the duration of the study. 2. women between 30 and 80 years of age 3. women having ≤5% of superficial cells on vaginal smear at baseline 4. women having a vaginal ph above 5 at baseline 5. women who have self-identified moderate or severe symptom(s) of vaginal atrophy exclusion criteria: main criteria: 1. clinically significant metabolic or endocrine disease (including diabetes mellitus) not controlled by medication 2. the administration of any investigational drug within 30 days of screening visit

Keywords: vulvovaginal atrophy (vva) vaginal atrophy atrophic vaginitis prasterone dhea intrarosa breast cancer aromatase inhibitor
prone or supine extubation in lomber spinal surgery

Conditions: Lumbar Spinal Stenosis

Summary: the aim of this study was to investigate the emergence quality of patients extubated on prone or supine position after lumbar spinal surgery. 60 patients with asa i-ii who underwent lumbar spinal surgery between 18-65 years of age were included in the study. patients with difficult intubation, bmi\> 35kg / m2, asthma and reactive airway problems, cardiovascular disease and obstructive sleep apnea will not be included in the study. initial data will be recorded after standard monitorization. induction is made by 2 mg / kg propofol, 1 mg / kg fentanyl and 0.5 mg / kg rocuronium will be added for muscle relaxation. patients with adequate muscle relaxation will be intubated with appropriate endotracheal tube and mechanical ventilation will be initiated. patients who are then given prone positions on the operating table will be supported with side gels. the head will be placed in the face gel in a neutral position. for intraoperative analgesia, remifentanil infusion at 0.2mcg / kg / min will be applied. after laminectomy is completed and control of bleeding, 1 mg / kg tramalol and 2 mg / kg metaclopromide will be applied to all patients. at the end of the skin stitching, the inhalation agent will be closed and the fresh gas will be turned 6 lt 100% o2. patients who want to be extubated in the prone position are left in this position while the other patients will be placed on the stretcher in a supine position for a short time. patients will be decurarized be neostigmin with atropine. extubation will be performed in both positions when spontanous ventilation begins at a tidal volume of 6ml / kg and a frequency of 12-20 / min. all the measures will be taken to ensure airway safety while the patient is extubated pron. the stretcher will be brought to the side of the operating table, investigator will be ready for reintubation and all the necessary persons will be with the patient. aspiration frequency will be recorded for each patient. during recovery after extubation, the severity of cough will be evaluated as mild (only once), less (more than one but not continuous) and severe (continuously for 5 seconds). aldrate scores of patient will be recorded and first 9-10 time is estimated from extubation time. vomiting, nausea, respiratory insufficiency, inability to control the airway and obvious desaturation if seen are also recorded.


Eligibility criteria:
inclusion criteria: * asa i-ii * 18-65 years old * need spinal surgery exclusion criteria: * difficult intubation * bmi\> 35kg / m2 * asthma and reactive airway problems * cardiovascular disease * obstructive sleep apnea